NYSE:AGNAllergan Stock Price, Forecast & News

Allergan's stock was trading at $185.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AGN shares have increased by 4.1% and is now trading at $193.02. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 12 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Allergan.

Allergan plc (NYSE:AGN) released its earnings results on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $4.57 by $0.65. The company had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.09 billion. Allergan had a positive return on equity of 8.46% and a negative net margin of 15.44%. The company's revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the business posted $4.29 earnings per share. View Allergan's earnings history.

Allergan announced a quarterly dividend on Wednesday, March 18th. Shareholders of record on Thursday, April 16th will be given a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 dividend on an annualized basis and a yield of 1.53%. The ex-dividend date of this dividend is Wednesday, April 15th. View Allergan's dividend history.

Allergan declared that its board has approved a stock buyback program on Tuesday, January 29th 2019, which permits the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 4.1% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

13 equities research analysts have issued 1-year price objectives for Allergan's stock. Their forecasts range from $165.00 to $203.00. On average, they expect Allergan's share price to reach $186.71 in the next twelve months. This suggests that the stock has a possible downside of 3.3%. View analysts' price targets for Allergan.

News articles about AGN stock have trended very negative recently, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allergan earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutAllergan.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Zogenix (ZGNX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.42%), State Street Corp (4.15%), Longview Partners Guernsey LTD (1.52%), Clearbridge Investments LLC (1.24%), JPMorgan Chase & Co. (1.12%) and Morgan Stanley (0.84%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi and Matthew M Walsh. View institutional ownership trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Nuveen Asset Management LLC, Clearbridge Investments LLC, State Street Corp, Segantii Capital Management Ltd, Scharf Investments LLC, Canyon Capital Advisors LLC, and Mackenzie Financial Corp. View insider buying and selling activity for Allergan.

AGN stock was bought by a variety of institutional investors in the last quarter, including Syquant Capital Sas, JPMorgan Chase & Co., ING Groep NV, BlackRock Inc., Water Island Capital LLC, Maso Capital Partners Ltd, Glazer Capital LLC, and Swiss National Bank. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, and Matthew M Walsh. View insider buying and selling activity for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $193.02.

Allergan has a market capitalization of $63.50 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.

The official website for Allergan is www.allergan.com.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]